HUP0200895A2 - Alfa-helyettesített karbonsavak benzimidazolszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Alfa-helyettesített karbonsavak benzimidazolszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0200895A2
HUP0200895A2 HU0200895A HUP0200895A HUP0200895A2 HU P0200895 A2 HUP0200895 A2 HU P0200895A2 HU 0200895 A HU0200895 A HU 0200895A HU P0200895 A HUP0200895 A HU P0200895A HU P0200895 A2 HUP0200895 A2 HU P0200895A2
Authority
HU
Hungary
Prior art keywords
group
substituted aryl
aralkyl
alkyl
saturated heterocyclic
Prior art date
Application number
HU0200895A
Other languages
English (en)
Inventor
Takashi Fujita
Toshihiko Fujiwara
Hidehito Honma
Harou Iwabuchi
Minoru Oguchi
Kunio Wada
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of HUP0200895A2 publication Critical patent/HUP0200895A2/hu
Publication of HUP0200895A3 publication Critical patent/HUP0200895A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány a-szubsztituált karbonsavszármazékokra vonatkozik,amelyeknek többek között inzulinrezisztenciát fokozó aktivitása,hipoglükémiás aktivitása, gyulladásgátló aktivitása van. A találmánytovábbá az említett a-szubsztituált karbonsavszármazékokgyógyászatilag elfogadható észtereire, gyógyászatilag elfogadhatóamidjaira és gyógyászatilag elfogadható sóira és ezeket tartalmazógyógyszerkészítményekre és alkalmazásukra vonatkozik. A találmányszerinti vegyületek (I) általános képletében R1, R2 és R3 azonos vagyeltérő jelentéssel hidrogénatomot vagy adott esetben szubsztituáltaril-, aralkil-, alkilszulfonil-, halogénalkil-szulfonil-,arilszulfonil- vagy aralkilszulfonil-csoportot jelent; A jelentésenitrogénatom vagy metincsoport; B jelentése oxigénatom vagy kénatom;W1 jelentése alkiléncsoport, W2 jelentése egyszeres kötés vagyalkiléncsoport; X jelentése halogén- vagy hidrogénatom vagy alkil-,halogénalkil-, alkoxi-, hidroxil-, ciano-, nitro-, cikloalkil-, adottesetben szubsztituált aril-, aralkil-, alifás acil-,cikloalkilkarbonil-, aril-karbonil-, aralkilkarbonil-, monociklusostípusú heteroaromás gyűrűvel szubsztituált karbonil-, karbamoil-,arilaminokarbonil- vagy aminocsoport; Y jelentése oxigénatom NR4 vagyS(O)p általános képletű csoport, és ebben a képletben p értéke 0, 1vagy 2; Z1 jelentése halogén- vagy hidrogénatom vagy alkil-, alkoxi-,alkiltio-, adott esetben szubsztituált aril-, aralkil-, ariloxi-.aralkiloxi-, cikloalkiloxi-, cikloalkiltio-, telített heterociklusosgyűrűs oxi-, monociklusos típusú heteroaromás gyűrűs oxi- ariltio-,aralkiltio-, telített heterociklusos gyűrűs tio-, monociklusos típusúheteroaromás gyűrűs tio-amino- vagy hidroxilcsoport, vagy Z2-O- vagyZ3-, S- csoport, Z2 jelentése adott esetben szubsztituált arilcsoportvagy telített heterociklusos gyűrűs csoport, Z3 jelentése alkil-,adott esetben szubsztituált aril-, aralkil- vagy cikloalkilcsoportvagy telített heterociklusos gyűrűs csoport; R4 jelentése alkil-,adott esetben szubsztituált aril- vagy aralkilcsoport. Ó
HU0200895A 1999-04-06 2000-04-06 Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use HUP0200895A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9928699 1999-04-06
JP21514199 1999-07-29

Publications (2)

Publication Number Publication Date
HUP0200895A2 true HUP0200895A2 (hu) 2002-11-28
HUP0200895A3 HUP0200895A3 (en) 2002-12-28

Family

ID=26440432

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200895A HUP0200895A3 (en) 1999-04-06 2000-04-06 Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use

Country Status (18)

Country Link
US (2) US6596751B2 (hu)
EP (1) EP1167357A4 (hu)
KR (1) KR20020060067A (hu)
CN (1) CN1208323C (hu)
AU (1) AU760163B2 (hu)
BR (1) BR0009593A (hu)
CA (1) CA2369871A1 (hu)
CZ (1) CZ20013593A3 (hu)
HK (1) HK1039939A1 (hu)
HU (1) HUP0200895A3 (hu)
IL (1) IL145732A0 (hu)
MX (1) MXPA01010109A (hu)
NO (1) NO20014849L (hu)
NZ (1) NZ514661A (hu)
PL (1) PL351898A1 (hu)
RU (1) RU2219172C2 (hu)
TR (1) TR200102908T2 (hu)
WO (1) WO2000059889A1 (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
WO2003002550A1 (en) * 2001-06-28 2003-01-09 Dr. Reddy's Research Foundation Dioxalane derivatives and a process for their preparation
WO2003010157A1 (en) * 2001-07-23 2003-02-06 Dr. Reddy's Research Foundation Dioxane derivatives and a process for their preparation
WO2003011814A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
WO2003011834A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2003053938A1 (en) * 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US20050250831A1 (en) * 2002-02-21 2005-11-10 Gibson Tracey A Peroxisome proliferator activated receptor modulators
ES2436467T3 (es) * 2002-03-20 2014-01-02 University Of Maryland Baltimore Un canal catiónico no selectivo en células neurales y antagonistas de Sur1 para el tratamiento de la inflamación del cerebro
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
TW200408628A (en) * 2002-08-02 2004-06-01 Sankyo Co Resorcinol and its derivatives
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
ATE469161T1 (de) 2002-08-08 2010-06-15 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
JP2006516254A (ja) 2003-01-06 2006-06-29 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体
WO2004073606A2 (en) * 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
KR101049348B1 (ko) * 2003-05-05 2011-07-13 톰슨 라이센싱 상이한 멀티플 콘텐츠 등급들을 갖는 텔레비전 신호를차단하는 시스템 및 방법
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ATE487484T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
JP5307397B2 (ja) * 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
TW200637856A (en) * 2005-01-24 2006-11-01 Sankyo Co Process for producing thiazolidinedion compound and intermediate thereof
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
EP2111224B1 (en) 2007-01-12 2016-07-13 University of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
WO2008098160A1 (en) * 2007-02-09 2008-08-14 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
EP2139330B1 (en) * 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
CN101679298B (zh) * 2007-04-05 2013-10-23 第一三共株式会社 稠合二环杂芳基衍生物
US8557867B2 (en) 2007-06-22 2013-10-15 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of NCCa-ATP channels for therapy
WO2010002075A1 (en) * 2008-07-02 2010-01-07 Pharmacostech Co., Ltd. Methods for preparing amide derivatives
JPWO2010101164A1 (ja) 2009-03-05 2012-09-10 第一三共株式会社 ピリジン誘導体
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102946882B (zh) * 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
CN104744282A (zh) * 2015-02-17 2015-07-01 南通恒盛精细化工有限公司 一种胰岛素增敏剂的制备工艺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942245A (en) 1987-04-20 1990-07-17 Kyorin Pharmaceutical Co., Ltd. Benzimidazole Derivatives
AU675689B2 (en) 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0760658B1 (en) 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JPH10504808A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP1007026A4 (en) 1997-01-17 2002-08-07 Merck & Co Inc INTEGRIN ANTAGONISTS
AU1903799A (en) 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
TWI250160B (en) 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound

Also Published As

Publication number Publication date
IL145732A0 (en) 2002-07-25
NO20014849D0 (no) 2001-10-05
CA2369871A1 (en) 2000-10-12
WO2000059889A1 (en) 2000-10-12
US20040002512A1 (en) 2004-01-01
HK1039939A1 (zh) 2002-05-17
AU760163B2 (en) 2003-05-08
US6596751B2 (en) 2003-07-22
US20030069294A1 (en) 2003-04-10
KR20020060067A (ko) 2002-07-16
CN1208323C (zh) 2005-06-29
CZ20013593A3 (cs) 2002-03-13
EP1167357A1 (en) 2002-01-02
CN1353694A (zh) 2002-06-12
BR0009593A (pt) 2002-06-18
RU2219172C2 (ru) 2003-12-20
PL351898A1 (en) 2003-06-30
HUP0200895A3 (en) 2002-12-28
TR200102908T2 (tr) 2002-04-22
MXPA01010109A (es) 2002-06-04
EP1167357A4 (en) 2002-06-05
NO20014849L (no) 2001-11-27
NZ514661A (en) 2003-06-30
AU3670700A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
HUP0200895A2 (hu) Alfa-helyettesített karbonsavak benzimidazolszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2505033A1 (en) Non-nucleoside reverse transcriptase inhibitors
HUP0401963A2 (hu) Karbonsavszármazékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
US9464079B2 (en) Treatment of proliferative disorders with a chemiluminescent agent
AR040352A1 (es) Derivados de indolinfenilsulfonamida
AR023060A1 (es) Uso de un compuesto que es un derivado de 2-ureido-1,3-tiazol, nuevos derivados de 2-ureido-1,3-tiazol, procedimientos para prepararlos y composicionesfarmaceuticas que los comprenden
HUP0301005A2 (hu) Pirrolotriazin kináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PL110780B1 (en) Method of producing new derivatives of quinazolone
KR960706482A (ko) 4,5-디아릴옥사졸 유도체(4,5-diaryloxazole derivatives)
HUP0105231A2 (hu) Heteroaril-szubsztituált kinolin-2-on-származék rákellenes szerek és a vegyületeket tartalmazó gyógyszerkészítmények
TR200102568T2 (tr) Amid türevleri.
IE831084L (en) Bicyclic carboxylic acids and esters thereof
RU2000110737A (ru) Производные бензамидина в качестве ингибиторов фактора xa
RU2000118792A (ru) ПРОИЗВОДНЫЕ БЕНЗАМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Хa
IE37194B1 (en) New isothiocyanobenzazoles and process for their producti
DE69524344D1 (de) Heterocyclisch substituierte Imidazolidine, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen
KR920018024A (ko) 피페리딘 유도체
HUP0202934A2 (hu) [(Aril-szulfonil)-amino]-szubsztituált hidroxámsav-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR034241A1 (es) Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
GB1265165A (hu)
EP0277725A3 (en) 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents
RU2077532C1 (ru) Производные хинолина или их соли, способы их получения, твердая фармацевтическая композиция
HUP0203884A2 (hu) Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ATE48839T1 (de) Heterocyclische phenoxyderivate die eine antihistamin-h2-wirkung besitzen.
AR028826A1 (es) Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees